Citations

Clear

623 citation(s) found for "Torres, V".

An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels
León, José de , Schoretsanitis, Georgios , Smith, Robert L. , Molden, Espen , Solismaa, Anssi , Seppälä, Niko , Kopeček, Miloslav , Švancer, Patrik , Olmos, I. Cánovas , Ricciardi, Carina , García, Celso Iglesias , Iglesias-Alonso, Ana , Ruan, Can‐Jun , Wang, Chuanyue , Wang, Gang , Tang, Yi‐lang , Kim, Yong Sik , Kim, Se Hyun , Rajkumar, Anto P. , González‐Esquivel, Dinora F. , Jung–Cook, Helgi , Verdoux, Hélène , Quilès, Clélia , Sanz, Emílio J. , Cuevas, Carlos De las , Cohen, Dan , Schulte, Peter F.J. , Yağcıoğlu, A. Elif Anıl , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O. , Kaithi, Arun R., Kane, John M. , Farooq, Saeed , Ng, Chee H. , Bilbily, John , Hiemke, Christoph , López‐Jaramillo, Carlos , McGrane, Ian R. , Lana, Fernando , Arrojo, Manuel , Rădulescu, Flavian Ștefan , Seifritz, Erich , Every‐Palmer, Susanna , Bebawi, Emmanuel , Bhattacharya, Rahul , Kelly, Deanna L. , Otsuka, Yuji , Lazáry, Judit , Torres, Rafael , Yécora, Agustín, Motuca, Mariano , Chan, Sherry Kit Wa , Berardis, Domenico De , Adebayo, Richard A. , Кирилочев, О.О. , Soloviev, A. G. , Fountoulakis, Konstantinos Ν. , Wilkowska, Alina , Cubała, Wiesław Jerzy , Ayub, Muhammad , Silva, Alzira , Bonelli, Raphael M., Crespo‐Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria Rosel , Tsukahara, Masaru , Gründer, Gerhard , Čelofiga, Andreja , Ristić, Dragana Ignjatović , Ortiz, Bruno Bertolucci , Elkis, Hélio , Siskind, Dan , Masmoudi, R. , Saffian, Shamin Mohd , Leung, Jonathan G. , Buckley, P.F. , Freudenreich, Oliver , Müller, Daniel J. , de Leon, Jose , Olmos, Ismael , Iglesias-Garcia, Celso , Spina, Edoardo , Ruan, Can-Jun , Wang, Chuan-Yue , Tang, Yi-Lang , Lin, Shih-Ku , Lane, Hsien-Yuan , Kim, Yong Sik , Kim, Se Hyun , Rajkumar, Anto P , González-Esquivel, Dinora F , Jung-Cook, Helgi , Baptista, Trino , Rohde, Christopher , Nielsen, Jimmi , Verdoux, Hélène , Quiles, Clelia , Sanz, Emilio J , De Las Cuevas, Carlos , Cohen, Dan , Schulte, Peter F J , Ertuğrul, Aygün , Anıl Yağcıoğlu, A Elif , Chopra, Nitin , McCollum, Betsy , Shelton, Charles , Cotes, Robert O , Kane, John M , Farooq, Saeed , Ng, Chee H , Bilbily, John , Hiemke, Christoph , López-Jaramillo, Carlos , McGrane, Ian , Lana, Fernando , Eap, Chin B , Every-Palmer, Susanna , Bousman, Chad A , Bebawi, Emmanuel , Bhattacharya, Rahul , Kelly, Deanna L , Otsuka, Yuji , Lazary, Judit , Motuca, Mariano , Chan, Sherry K W , Zolezzi, Monica , Ouanes, Sami , De Berardis, Domenico , Grover, Sandeep , Procyshyn, Ric M , Adebayo, Richard A , Kirilochev, Oleg O , Soloviev, Andrey , Fountoulakis, Konstantinos N , Wilkowska, Alina , Cubała, Wiesław J , Ayub, Muhammad , Silva, Alzira , Villagrán-Moreno, José M , Crespo-Facorro, Benedicto , Temmingh, Henk , Decloedt, Eric , Pedro, Maria R , Takeuchi, Hiroyoshi , Tsukahara, Masaru , Gründer, Gerhard , Sagud, Marina , Celofiga, Andreja , Ignjatovic Ristic, Dragana , Ortiz, Bruno B , Elkis, Helio , Pacheco Palha, António J , LLerena, Adrián , Fernandez-Egea, Emilio , Siskind, Dan , Weizman, Abraham , Masmoudi, Rim , Mohd Saffian, Shamin , Leung, Jonathan G , Buckley, Peter F , Marder, Stephen R , Citrome, Leslie , Freudenreich, Oliver , Correll, Christoph Ulrich , Müller, Daniel J , Kopecek, Miloslav , Arrojo-Romero, Manuel , Schoretsanitis, Georgios , Rohde, Christopher , Nielsen, Jimmi , Bousman, Chad , LLerena, Adrián , Citrome, Leslie

Mayo Clinic

Pharmacopsychiatry | December 15, 2021 | Volume: 55 | Issue: 02 | Pages: 73-86

10.1055/a-1625-6388 | PMID 34911124 Get It

Abstract This international guideline proposes improving clozapine package inserts worldwide by using ancestry-based dosing and titration. Adverse drug reaction (ADR) databases suggest that clozapine is the third most toxic drug in the United States (US), and it produces four times higher worldwide pneumonia mortality than that by agranulocytosis or myocarditis. For trough steady-state clozapine serum concentrations, the therapeutic reference range is narrow, from 350 to 600 ng/mL with the potential for toxicity and ADRs as concentrations increase. Clozapine is mainly metabolized by CYP1A2 (female non-smokers, the lowest dose; male smokers, the highest dose). Poor metabolizer status through phenotypic conversion is associated with co-prescription of inhibitors (including oral contraceptives and valproate), obesity, or inflammation with C-reactive protein (CRP) elevations. The Asian population (Pakistan to Japan) or the Americas’ original inhabitants have lower CYP1A2 activity and require lower clozapine doses to reach concentrations of 350 ng/mL. In the US, daily doses of 300–600 mg/day are recommended. Slow personalized titration may prevent early ADRs (including syncope, myocarditis, and pneumonia). This guideline defines six personalized titration schedules for inpatients: 1) ancestry from Asia or the original people from the Americas with lower metabolism (obesity or valproate) needing minimum therapeutic dosages of 75–150 mg/day, 2) ancestry from Asia or the original people from the Americas with average metabolism needing 175–300 mg/day, 3) European/Western Asian ancestry with lower metabolism (obesity or valproate) needing 100–200 mg/day, 4) European/Western Asian ancestry with average metabolism needing 250–400 mg/day, 5) in the US with ancestries other than from Asia or the original people from the Americas with lower clozapine metabolism (obesity or valproate) needing 150–300 mg/day, and 6) in the US with ancestries other than from Asia or the original people from the Americas with average clozapine metabolism needing 300–600 mg/day. Baseline and weekly CRP monitoring for at least four weeks is required to identify any inflammation, including inflammation secondary to clozapine rapid titration.
Aggressive Afterload Lowering to Improve the Right Ventricle: A New Target for Medical Therapy in Pulmonary Arterial Hypertension?
Vizza, Carmine Dario , Benza, Raymond L. , White, R. James , Adir, Yochai , Andreassen, Arne K., Balasubramanian, Vijay , Bartolome, Sonja, Carlsen, Jørn , Camacho, Rafael Enrique Conde, Ford, H. James , Humbert, Marc , Naeije, Robert , Orfanos, Stylianos E. , Oudiz, Ronald J. , Perrone, Sergio V. , Shlobin, Oksana A. , Torres, Fernando , Vachiéry, Jean Luc, Wang, Kuo‐Yang , Liu, Yan , Golden, Gil, Matsubara, Hiromi , Benza, Raymond L. , Oudiz, Ronald , Lang, Iréne , Badagliacca, Roberto , Rosenkranz, Stephan , Andreassen, Arne K., Blanco, Isabel , Bourge, Robert C. , Camacho, Rafael Enrique Conde , D’Alto, Michele , Farber, Harrison W. , Frantz, Robert P. , Ghio, Stefano , Gomberg‐Maitland, Mardi , Simon, Marc A. , Sitbon, Olivier , Vachiéry, Jean‐Luc , Yacoub, Magdi Habib

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | December 14, 2021 | Volume: 205 | Issue: 7 | Pages: 751-760

10.1164/rccm.202109-2079pp | PMID 34905704 Get It

Abstract Despite numerous therapeutic advances in pulmonary arterial hypertension, patients continue to suffer high morbidity and mortality, particularly considering a median age of 50 years. This article explores whether early, robust reduction of right ventricular afterload would facilitate substantial improvement in right ventricular function and thus whether afterload reduction should be a treatment goal for pulmonary arterial hypertension. The earliest clinical studies of prostanoid treatment in pulmonary arterial hypertension demonstrated an important link between lowering mean pulmonary arterial pressure (or pulmonary vascular resistance) and improved survival. Subsequent studies of oral monotherapy or sequential combination therapy demonstrated smaller reductions in mean pulmonary arterial pressure and pulmonary vascular resistance. More recently, retrospective reports of initial aggressive prostanoid treatment or initial combination oral and parenteral therapy have shown marked afterload reduction along with significant improvements in right ventricular function. Some data suggest that reaching threshold levels for pressure or resistance (components of right ventricular afterload) may be key to interrupting the self-perpetuating injury of pulmonary vascular disease in pulmonary arterial hypertension and could translate into improved long-term clinical outcomes. Based on these clues, the authors postulate that improved clinical outcomes might be achieved by targeting significant afterload reduction with initial oral combination therapy and early parenteral prostanoids.
Asymptomatic Pyuria as a Prognostic Biomarker in Autosomal Dominant Polycystic Kidney Disease
Jones, Brian E. , Mkhaimer, Yaman , Rangel, Laureano J. , Chedid, Maroun , Schulte, Phillip J. , Mohamed, Alaa K. , Neal, Reem M. , Zubidat, Dalia , Randhawa, Amarjyot K. , Hanna, Christian , Gregory, Adriana , Kline, Timothy L. , Senum, Sarah R. , Harris, Peter C. , Torres, Vicente E. , Mkhaimer, Yaman G , Gregory, Adriana V, El-Zoghby, Ziad , Senum, Sarah R , Harris, Peter C , Torres, Vicente E , Hanna, Christian , Zoghby, Ziad , Chebib, Fouad T.

Mayo Clinic

Kidney360 | December 8, 2021 | Volume: 3 | Issue: 3 | Pages: 465-476

10.34067/kid.0004292021 | PMID 35582184 Get It

Key Points Asymptomatic pyuria is associated with kidney failure and faster kidney function decline irrespective of the ADPKD gene and cystic growth. The eGFR decline occurred after detection of asymptomatic pyuria without significant changes in the rate of total kidney volume growth. This study supports the use of asymptomatic pyuria as an enriching prognostic biomarker to predict faster disease progression. Background Autosomal dominant polycystic kidney disease (ADPKD) has phenotypic variability only partially explained by established biomarkers that do not readily assess pathologically important factors of inflammation and kidney fibrosis. We evaluated asymptomatic pyuria (AP), a surrogate marker of inflammation, as a biomarker for disease progression. Methods We performed a retrospective cohort study of adult patients with ADPKD. Patients were divided into AP and no pyuria (NP) groups. We evaluated the effect of pyuria on kidney function and kidney volume. Longitudinal models evaluating kidney function and kidney volume rate of change with respect to incidences of AP were created. Results There were 687 included patients (347 AP, 340 NP). The AP group had more women (65% versus 49%). Median ages at kidney failure were 86 and 80 years in the NP and AP groups (log rank, P =0.49), respectively, for patients in Mayo Imaging Class (MIC) 1A–1B as compared with 59 and 55 years for patients in MIC 1C–1D–1E (log rank, P =0.02), respectively. Compared with the NP group, the rate of kidney function (ml/min per 1.73 m 2 per year) decline shifted significantly after detection of AP in the models, including all patients (−1.48; P <0.001), patients in MIC 1A–1B (−1.79; P <0.001), patients in MIC 1C–1D–1E (−1.18; P <0.001), and patients with PKD1 (−1.04; P <0.001). Models evaluating kidney volume rate of growth showed no change after incidence of AP as compared with the NP group. Conclusions AP is associated with kidney failure and faster kidney function decline irrespective of the ADPKD gene, cystic burden, and cystic growth. These results support AP as an enriching prognostic biomarker for the rate of disease progression.
Acute Treatment Effects on GFR in Randomized Clinical Trials of Kidney Disease Progression
Neuen, Brendon L. , Vonesh, Edward F. , Chaudhari, Juhi, Miao, Shiyuan , Fervenza, Fernando C. , Floege, Jürgen , Goicoechea, Marián , Imai, Enyu , Jafar, Tazeen H. , Lewis, Julia B. , Li, Philip Kam‐Tao , Locatelli, Francesco , Maes, Bart , Praga, Manuel , Woodward, Mark , Xie, Di , Inker, Lesley A. , Floege, Jürgen , Herrington, William G , Li, Philip Kam-Tao , Torres, Vicente E , Wanner, Christoph , Woodward, Mark , Greene, Tom , Fervenza, Fernando C , Tighiouart, Hocine , Heerspink, Hiddo J.L. , Chan, Tak Mao , Perrone, Ronald D. , Perna, Annalisa , Schena, Francesco Paolo , Wetzels, Jack F.M. , Greene, Tom

Mayo Clinic

Journal of the American Society of Nephrology | December 3, 2021 | Volume: 33 | Issue: 2 | Pages: 291-303

10.1681/asn.2021070948 | PMID 34862238 Get It

Background Acute changes in GFR can occur after initiation of interventions targeting progression of CKD. These acute changes complicate the interpretation of long-term treatment effects. Methods To assess the magnitude and consistency of acute effects in randomized clinical trials and explore factors that might affect them, we performed a meta-analysis of 53 randomized clinical trials for CKD progression, enrolling 56,413 participants with at least one estimated GFR measurement by 6 months after randomization. We defined acute treatment effects as the mean difference in GFR slope from baseline to 3 months between randomized groups. We performed univariable and multivariable metaregression to assess the effect of intervention type, disease state, baseline GFR, and albuminuria on the magnitude of acute effects. Results The mean acute effect across all studies was −0.21 ml/min per 1.73 m 2 (95% confidence interval, −0.63 to 0.22) over 3 months, with substantial heterogeneity across interventions (95% coverage interval across studies, −2.50 to +2.08 ml/min per 1.73 m 2 ). We observed negative average acute effects in renin angiotensin system blockade, BP lowering, and sodium-glucose cotransporter 2 inhibitor trials, and positive acute effects in trials of immunosuppressive agents. Larger negative acute effects were observed in trials with a higher mean baseline GFR. Conclusion The magnitude and consistency of acute GFR effects vary across different interventions, and are larger at higher baseline GFR. Understanding the nature and magnitude of acute effects can help inform the optimal design of randomized clinical trials evaluating disease progression in CKD.
Clinico-Epidemiological Features of Elderly Patients with Peripheral T-Cell Lymphoma Not Otherwise Specified: A Study from the Grupo De Estudio Latinoamericano De Linfoproliferativos (GELL)
Idrobo, Henry , Castro, Denisse , Fiad, Lorena , Collado, Yesenia M. Huerta-, Otero, Victoria, Paredes, Sally , García-Robledo, Juan Esteban , Lasso, Juan Felipe, Martínez‐Cordero, Humberto , Osorio-Gómez, Ana María , Sanchez-Perea, Julian Andres, Viera, Marialejandra Alejandra Torres, Garcia-Robledo, Juan Esteban , Valcárcel, Bryan , Villela, Luís , Viera, Maria Alejandra Torres, Beltran, Brady E. , Castillo, Jorge J. , Malpica, Luis

Mayo Clinic

Blood | November 24, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 2468-2468

10.1182/blood-2021-153849 Get It

Abstract Introduction: Peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) is the most common PTCL subtype, accounting for approximately 25% of all PTCL cases. The median age at diagnosis is 60 years and is more prevalent among males. Currently, most epidemiological data on T- and NK-cell lymphomas come from developed countries. Thus, very few data are available regarding this condition in Latin American countries, especially in those aged 60 years and older. The Latin American Group of Lymphoproliferative Disorders (GELL) has previously reported on the impact of serum albumin level in survival outcomes in PTCL-NOS. Therefore, we aim to evaluate the clinical, demographic, and outcome patterns of elderly patients with PTCL-NOS. Methods: We conducted an observational, retrospective study of newly diagnosed PTCL-NOS between January 2000 and December 2020. Patient must be aged 60 years and older. All clinical data were retrieved from clinical records at the different participating institutions. The study outcomes were overall survival (OS) and progression-free survival (PFS). The International Prognostic Index (IPI), the Prognostic Index for T-cell lymphoma (PIT), and the NCCN IPI scores were used for risk stratification. Kaplan-Meier and log-rank test were used for survival analysis. Univariate and multivariate Cox regression analysis were used to estimate hazard ratios (HR) with a 95% confidence interval (CI). Outcomes with a p-value &lt;0.05 were considered statistically significant. Results: A total of 107 patients were included; median age at diagnosis was 72 years (range 60-92), 61% were male, 46% had an ECOG ≥2, 70% had stage III-IV, and 15% had more than one extranodal site. The IPI, PIT and NCCN-IPI scores stratified 51%, 69%, and 74% of patients as high- / high-intermediate risk, respectively. Seventy-four (69%) patients received first-line systemic therapy. Most patients (53%) were managed with CHOP/CHOP-like regimen, followed by CHOEP (19%). The overall response (OR) rate to first-line therapy was 61% (complete response, CR 41%). Salvage therapy was given to only 9 patients; the OR rate was 44% (CR 11%). With a median follow-up of 29 months (95% CI 13-45 months), the 2-year OS was 46% (95% CI 36-59), with median survival time of 16 months (95% CI 10-NR). In the multivariate analysis, patients with serum albumin levels &lt;3.5 g/dL had median survival of 7 months (95% CI 3-20) and 2-year OS rate of 24% (95% CI 13-46%), while patients with albumin ≥3.5 g/dL did not reach the median survival time and had a 2-yOS rate of 67% (95% CI 36-65%) (p&lt;0.0001) (Table 1, Figure 1). Patients with a lymphocyte-to-monocyte ratio (LMR) &gt;7.6 had a median OS of 8 months (95% CI 6-NR) and a 2-year OS of 10% (95% CI 2-65), while patients with a LMR ≤7.6 did not reach the median OS and had a 2-year OS of 57% (95% CI 45-72) (p = 0.0108) (Table 1, Figure 1). Conclusions: This large cohort of Latin American PTCL-NOS patients aged ≥60 years showed overall response rates comparable to previously published data. However, survival rates were shorter compared to those reported in developed countries. In this study, we again confirmed low serum albumin level (&lt;3.5 g/dL) as an adverse prognostic factor for OS in PTCL-NOS, and independent from the IPI, PIT and NCCN-IP scores. Additionally, we describe for first time in a Latin American cohort the impact of the LMR on survival, demonstrating poor outcomes in those with LMR &gt;7.6. We are currently validating our findings in a prospective cohort of Latin American PTCL patients and to improve clinical decision-making in those deemed at high-risk for early mortality. Figure 1 Figure 1. Disclosures Otero: Astra Zeneca: Current Employment. Castillo: Abbvie: Consultancy, Research Funding; BeiGene: Consultancy, Research Funding; Pharmacyclics: Consultancy, Research Funding; Janssen: Consultancy; Roche: Consultancy; TG Therapeutics: Research Funding.
The Impact of Pacritinib on Myelofibrosis Symptoms in Patients with Moderate and Severe Thrombocytopenia: A Retrospective Analysis of Patients in the Persist-2 Study
Palmer, Jeanne , Rampal, Raajit K. , Buckley, Sarah , Roman‐Torres, Karisse, Harrison, Claire , Craig, Adam R., Mesa, Ruben A. , Oh, Stephen T. , Verstovšek, Srđan , Mascarenhas, John , Vannucchi, Alessandro M. , Kiladjian, Jean‐Jacques , Bose, Prithviraj , Gerds, Aaron T.

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 3628-3628

10.1182/blood-2021-144505 Get It

Abstract Introduction: Thrombocytopenia, a hallmark of cytopenic myelofibrosis (MF), is associated with poor survival and quality of life impairment. Patients with MF and moderate or severe thrombocytopenia (platelet counts &lt;100x10 9/L, &lt;50x10 9/L) tend to have high symptom burden as measured by the Total Symptom Score (TSS), driven largely by physical functioning symptoms (Mesa R et al, ASH 2021 abstract in submission). Pacritinib, an investigational JAK2/IRAK1 inhibitor, was studied in patients with platelet counts ≤100x10 9/L in the PERSIST-2 trial. Unlike the pivotal studies upon which available JAK1/2 inhibitors were approved that relied on a modified TSS version that excluded 'tiredness' from the response analysis, PERSIST-2 included 'tiredness' as part of TSS and found response rates of 25% for pacritinib vs. 14% for best available therapy (BAT), P=0.08. Here, we retrospectively analyzed TSS on PERSIST-2 using the modified scoring system. In addition, we evaluated the impact of pacritinib and BAT, including ruxolitinib, on MF symptoms including 'tiredness' and 'inactivity'. Methods: All PERSIST-2 patients in the intention-to-treat population randomized at least 22 weeks prior to the end of the study were included. PERSIST-2 randomized patients 1:1:1 to pacritinib 200mg BID, pacritinib 400mg daily, or BAT (including ruxolitinib). The modified TSS score was calculated as the sum of individual symptom scores for early satiety, abdominal discomfort, rib pain, night sweats, itching, and bone pain ('tiredness' and 'inactivity' were not included), and response was defined as a ≥50% reduction in score from baseline to week 24. Symptoms were categorized as physical function-related (tiredness, inactivity), spleen-related (satiety, abdominal discomfort, rib pain), or cytokine-related (sweats, itching, bone pain). The Wilcoxon Rank Sum test was used to compare differences in scores. Results: The analysis included 74 patients randomized to pacritinib 200mg BID and 72 to BAT; an additional 75 were randomized to pacritinib 400mg QD (dose no longer in development). At baseline, 39% had moderate and 46% had severe thrombocytopenia. Ruxolitinib was selected as BAT in 45% of patients with moderate and 38% with severe thrombocytopenia. The co-primary endpoint for the study - TSS response rate in pooled pacritinib arms versus BAT - showed a significant difference using the modified TSS: 30% vs. 14%, P=0.008. Similarly, the modified TSS response rate was higher for patients treated with pacritinib 200mg BID compared to BAT (35% vs. 14%, P=0.004, Figure 1a). Among patients on the BAT arm, modified TSS response rates were modestly higher for patients who received ruxolitinib prior to week 24 (19% [n=6/32]) compared to those who did not (10% [n=4/40]), though both were lower than response rates with pacritinib. Patients on the pacritinib 200mg BID arm experienced greater percentage reductions in individual myelofibrosis symptoms between baseline and week 24 compared to BAT, both in patients with moderate and severe thrombocytopenia (Figure 1b, 1c). For physical function symptoms, severity was reduced more on pacritinib 200mg BID compared to BAT by week 24 (median reduction in tiredness: 30% vs. 13%, P=0.0261; inactivity: 22% vs. 7%, P=0.099). Among patients with severe thrombocytopenia, symptom improvement was minimal on BAT (Figure 1b). Conclusion: The symptom benefit of pacritinib in patients with moderate and severe thrombocytopenia is demonstrated in the PERSIST-2 study. A significant reduction in symptoms was observed in patients treated with pacritinib 200mg BID, the dose being studied in an ongoing Phase 3 trial (PACIFICA), compared to BAT. Furthermore, the modified TSS response rate of 35% in patients treated with pacritinib 200mg BID is comparable to that reported for approved JAK1/2 inhibitors in patients with higher platelet counts, suggesting the potential for pacritinib to address the unmet need of patients with cytopenic myelofibrosis. Figure 1 Figure 1. Disclosures Palmer: CTI BioPharma: Consultancy, Research Funding; Protagonist: Consultancy, Research Funding; Incyte: Research Funding; PharmaEssentia: Research Funding; Sierra Oncology: Consultancy, Research Funding. Mesa: Incyte Corporation: Consultancy, Research Funding; Samus: Research Funding; Sierra Oncology: Consultancy, Research Funding; CTI: Research Funding; Novartis: Consultancy; Celgene: Research Funding; Pharma: Consultancy; La Jolla Pharma: Consultancy; Constellation Pharmaceuticals: Consultancy, Research Funding; CTI: Research Funding; Abbvie: Research Funding; Gilead: Research Funding; Genentech: Research Funding; Promedior: Research Funding; AOP: Consultancy. Oh: Abbvie: Membership on an entity's Board of Directors or advisory committees; Blueprint Medicines: Membership on an entity's Board of Directors or advisory committees; Celgene Bristol Myers Squibb: Membership on an entity's Board of Directors or advisory committees; Constellation: Membership on an entity's Board of Directors or advisory committees; CTI Biopharma: Membership on an entity's Board of Directors or advisory committees; Disc Medicine: Membership on an entity's Board of Directors or advisory committees; Geron: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; Kartos Therapeutics: Membership on an entity's Board of Directors or advisory committees; PharamaEssentia: Membership on an entity's Board of Directors or advisory committees; Sierra Oncology: Membership on an entity's Board of Directors or advisory committees. Rampal: Sierra Oncology: Consultancy; Novartis: Consultancy; BMS/Celgene: Consultancy; Stemline: Consultancy, Research Funding; Jazz Pharmaceuticals: Consultancy; Constellation: Research Funding; Kartos: Consultancy; Disc Medicine: Consultancy; Blueprint: Consultancy; Pharmaessentia: Consultancy; Incyte: Consultancy, Research Funding; Memorial Sloan Kettering: Current Employment; Abbvie: Consultancy; CTI: Consultancy. Buckley: CTI Biopharm: Current Employment. Roman-Torres: CTI Biopharm: Current Employment. Verstovsek: Protagonist Therapeutics: Research Funding; Genentech: Research Funding; Gilead: Research Funding; Incyte Corporation: Consultancy, Research Funding; Celgene: Consultancy, Research Funding; NS Pharma: Research Funding; AstraZeneca: Research Funding; Blueprint Medicines Corp: Research Funding; CTI BioPharma: Research Funding; Promedior: Research Funding; Ital Pharma: Research Funding; PharmaEssentia: Research Funding; Roche: Research Funding; Novartis: Consultancy, Research Funding; Sierra Oncology: Consultancy, Research Funding; Constellation: Consultancy; Pragmatist: Consultancy. Mascarenhas: Sierra Oncology: Consultancy, Membership on an entity's Board of Directors or advisory committees; Merck: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Merus: Research Funding; Geron: Consultancy; Gilead: Consultancy, Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Forbius: Research Funding; Genentech/Roche: Consultancy, Membership on an entity's Board of Directors or advisory committees; Novartis: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Geron: Consultancy, Research Funding; Constellation: Consultancy, Membership on an entity's Board of Directors or advisory committees; Promedior: Consultancy, Membership on an entity's Board of Directors or advisory committees; Kartos: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; AbbVie: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Celgene/BMS: Consultancy, Membership on an entity's Board of Directors or advisory committees; Incyte: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding; Prelude: Consultancy; Galecto: Consultancy; CTI Biopharm: Consultancy, Membership on an entity's Board of Directors or advisory committees, Research Funding. Vannucchi: AbbVie: Membership on an entity's Board of Directors or advisory committees; Bristol Myers Squibb: Honoraria, Membership on an entity's Board of Directors or advisory committees; Novartis: Honoraria, Membership on an entity's Board of Directors or advisory committees; Incyte Corporation: Honoraria, Membership on an entity's Board of Directors or advisory committees. Kiladjian: CTI BioPharma: Membership on an entity's Board of Directors or advisory committees, Research Funding; AP Orphan: Membership on an entity's Board of Directors or advisory committees; Incyte: Membership on an entity's Board of Directors or advisory committees; AbbVie: Membership on an entity's Board of Directors or advisory committees; Celgene/BMS: Membership on an entity's Board of Directors or advisory committees; Novartis: Membership on an entity's Board of Directors or advisory committees; PharmaEssentia: Membership on an entity's Board of Directors or advisory committees. Harrison: Galacteo: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Promedior: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Constellation Pharmaceuticals: Research Funding; Incyte Corporation: Speakers Bureau; Roche: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Janssen: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; BMS: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Keros: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Shire: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Abbvie: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; AOP Orphan Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Sierra Oncology: Honoraria; Gilead Sciences: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Geron: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; CTI BioPharma: Membership on an entity's Board of Directors or advisory committees, Speakers Bureau; Celgene: Honoraria, Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau; Novartis: Membership on an entity's Board of Directors or advisory committees, Research Funding, Speakers Bureau. Bose: Novartis: Honoraria; NS Pharma: Research Funding; Pfizer: Research Funding; Constellation Pharmaceuticals: Research Funding; Blueprint Medicines: Honoraria, Research Funding; Kartos Therapeutics: Honoraria, Research Funding; Incyte Corporation: Honoraria, Research Funding; Promedior: Research Funding; CTI BioPharma: Honoraria, Research Funding; Sierra Oncology: Honoraria; Astellas: Research Funding; BMS: Honoraria, Research Funding; Celgene Corporation: Honoraria, Research Funding. Craig: CTI BioPharma: Current Employment. Gerds: PharmaEssentia Corporation: Consultancy; CTI BioPharma: Research Funding; Sierra Oncology: Consultancy; AbbVie: Consultancy; Celgene/Bristol Myers Squibb: Consultancy; Constellation: Consultancy; Novartis: Consultancy.
474 Phase 1 study of SEA-TGT, a human, nonfucosylated anti-TIGIT monoclonal antibody with enhanced immune-effector function, in patients with advanced malignancies (SGNTGT-001, trial in progress)
Garralda, Elena , Oberoi, H.K., Herrera, Alex F. , Forero‐Torres, Andres , Ansell, Stephen, Davar, Diwakar , Ribrag, Vincent , Sarkozy, Clémentine , Mehta, Amitkumar , Curigliano, Giuseppe , Belli, Carmen , Zain, Jasmine , Sanborn, Rachel E , Dumbrava, Ecaterina E.

Mayo Clinic

Regular and Young Investigator Award Abstracts | November 9, 2021 | Volume: No volume available | Issue: No issue available | Pages: A503-A503

10.1136/jitc-2021-sitc2021.474 Get It

Ferroptosis Promotes Cyst Growth in Autosomal Dominant Polycystic Kidney Disease Mouse Models
Zhang, Xiaoqin , Li, Xiaoyan , Ding, Hao , Torres, Vicente E. , Yu, Chen , Li, Xiaogang , Li, Linda Xiaoyan , Torres, Vicente E , Li, Xiaogang

Mayo Clinic

Journal of the American Society of Nephrology | October 29, 2021 | Volume: 32 | Issue: 11 | Pages: 2759-2776

10.1681/asn.2021040460 | PMID 34716241 Get It

Significance Statement This study demonstrates for the first time a role of ferroptosis in ADPKD. We show the Pkd1 mutation makes renal epithelial cells prone to ferroptosis through the dysregulation of iron and lipid metabolism. It also suggests the main form of regulated cell death in ADPKD kidneys is ferroptotic but not apoptotic, which helps clarify the controversy over the role of apoptosis in ADPKD. In addition, we found that induction of ferroptosis by erastin promotes cyst growth in Pkd1RC/RC mice, whereas inhibition of ferroptosis by Fer-1 delays cyst growth in rapidly and slowly progressive ADPKD mouse models. These observations suggest management of ferroptosis may be a novel strategy for the treatment of this disease. Background Autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disease, is regulated by different forms of cell death, including apoptosis and autophagy. However, the role in ADPKD of ferroptosis, a recently discovered form of cell death mediated by iron and lipid metabolism, remains elusive. Methods To determine a pathophysiologic role of ferroptosis in ADPKD, we investigated whether the absence of Pkd1 (encoding polycystin-1) affected the expression of key factors involved in the process of ferroptosis, using Western blot and qRT-PCR analysis in Pkd1 mutant renal cells and tissues. We also examined whether treatment with erastin, a ferroptosis inducer, and ferrostain-1, a ferroptosis inhibitor, affected cyst growth in Pkd1 mutant mouse models. Results We found that kidney cells and tissues lacking Pkd1 exhibit extensive metabolic abnormalities, including reduced expression of the system Xc − amino acid antiporter (critical for import of cystine), of iron exporter (ferroportin), and of GPX4 (a key and negative regulator of ferroptosis). The abnormalities also include increased expression of iron importers (TfR1, DMT1) and HO-1, which in turn result in high iron levels, low GSH and GPX4 activity, increased lipid peroxidation, and propensity to ferroptosis. We further found that erastin increased, and ferrostatin-1 inhibited ferroptotic cell death and proliferation of Pkd1 -deficient cells in kidneys from Pkd1 mutant mice. A lipid peroxidation product increased in Pkd1 -deficient cells, 4HNE, promoted the proliferation of survived Pkd1 mutant cells via activation of Akt, S6, Stat3, and Rb during the ferroptotic process, contributing to cyst growth. Conclusion These findings indicate that ferroptosis contributes to ADPKD progression and management of ferroptosis may be a novel strategy for ADPKD treatment.
S3278 Peppermint Oil Is Highly Effective for the Treatment of Adults With IBS: RESULTS From a Self-Reported Survey
Chey, William D. , Lacy, Brian E. , Zeitzoff, Linda , Torres, Krysmarú Araujo , Cekola, Pamela , Epstein, Michael, Cash, Brooks D. , Cohen, Sarah S.

Mayo Clinic

American Journal of Gastroenterology | October 24, 2021 | Volume: 116 | Issue: 1 | Pages: S1351-S1351

10.14309/01.ajg.0000786644.04884.e5 Get It